TriNet Group (TNET) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.17 per share a year ago.

Reynolds Consumer Products (REYN) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.41 per share a year ago.

As Nvidia (NASDAQ: NVDA) stock continues to make history as the first company to hit a $5 trillion market cap, insights from OpenAI's ChatGPT suggest the semiconductor giant is likely to double this value in the coming years.

In the words of JPMorgan analysts, there are harmonizing tailwinds in play, including rate reductions, tariff impacts, tax-related stimulus, and the wealth effect, to drive business in 2026 and over the long term.

Envela (ELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PARR readies Q3 results as strong refining margins face logistics headwinds and uncertain earnings momentum.

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Extreme Networks (EXTR) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.17 per share a year ago.

Fiserv (FI) came out with quarterly earnings of $2.04 per share, missing the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.3 per share a year ago.

Etsy (ETSY) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.45 per share a year ago.

Idex (IEX) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.93 per share. This compares to earnings of $1.9 per share a year ago.

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.95 per share a year ago.

Kraft Heinz (KHC) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.75 per share a year ago.

Hayward Holdings, Inc. (HAYW) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.

ProPetro Holding (PUMP) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.12 per share a year ago.

Masco (MAS) came out with quarterly earnings of $0.97 per share, missing the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.08 per share a year ago.

Nucor Corporation is upgraded to Strong Buy with a $172 price target, following a significant Q3'25 earnings beat and optimistic market outlook. NUE is poised for growth from data center construction, power grid expansion, reindustrialization, and ongoing steel import tariffs supporting domestic demand. Capital investments in new mills and data center infrastructure position NUE for margin expansion and diversified revenue streams over the next several years.

Apple Inc. (NASDAQ: AAPL) stock trades near its all-time high.

Cherry-picking individual MLPs has so far worked better for me than going long AMLP, which tracks a basket of midstream players. However, the recent pullback of AMLP has created an interesting opportunity to enter. Since the oil and natural gas markets have become more uncertain, capturing the diversification benefit of AMLP with ~8.3% yield sounds attractive.

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. New study results showed that positive Week 12 data across multiple higher-order response measures continue to deepen into Week 28 regardless of prior treatment. These results were then durable for at least three months off drug. Additionally, rosnilimab was well-tolerated with …